ArticleThe journal of prevention of Alzheimer's disease2016
Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.
Article in The journal of prevention of Alzheimer's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dementia registries around the globe and their applications: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Pooled it
- Development of a web platform to advance data-driven recruitment for ADRD research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The AROMHA brain health test is a remote olfactory assessment to screen for cognitive impairment.Scientific reports · 2025Article
- Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.Alzheimer's research & therapy · 2023Observational
- Digital health technologies and Alzheimer's disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?Alzheimer's research & therapy · 2023Article
- Computer-based cognitive tests and cerebral pathology among Japanese older adults.BMC geriatrics · 2023Article
- Progression from Prodromal Alzheimer's Disease to Mild Alzheimer's Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions.Journal of Alzheimer's disease : JAD · 2023Article
- Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Validity of Online Versus In-Clinic Self-Reported Everyday Cognition Scale.The journal of prevention of Alzheimer's disease · 2022Article
- Serum Corticosterone and Insulin Resistance as Early Biomarkers in the hAPP23 Overexpressing Mouse Model of Alzheimer's Disease.International journal of molecular sciences · 2021Article
- Considerations on the clinical development of COVID-19 vaccine from trial design perspectives.Human vaccines & immunotherapeutics · 2021Article
- Digital Dementia Registry Bavaria-digiDEM Bayern: study protocol for a multicentre, prospective, longitudinal register study.BMJ open · 2021Article
- A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Programme.The journal of prevention of Alzheimer's disease · 2021Article
- The IGNITE trial: Participant recruitment lessons prior to SARS-CoV-2.Contemporary clinical trials communications · 2020Article
- Race- and Sex-Based Disparities in Alzheimer's Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective.Journal of Alzheimer's disease reports · 2020Review
- The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease.Scientific reports · 2020Article
- The "rights" of precision drug development for Alzheimer's disease.Alzheimer's research & therapy · 2019Review
- GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.Frontiers in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Alzheimer's disease (AD) drug development is costly, time-consuming, and inefficient. Trial site functions, trial design, and patient recruitment for trials all require improvement. The Global Alzheimer Platform (GAP) was initiated in response to these challenges. Four GAP work streams evolved in the US to address different trial challenges: 1) registry-to-cohort web-based recruitment; 2) clinical trial site activation and site network construction (GAP-NET); 3) adaptive proof-of-concept clinical trial design; and 4) finance and fund raising. GAP-NET proposes to establish a standardized network of continuously funded trial sites that are highly qualified to perform trials (with established clinical, biomarker, imaging capability; certified raters; sophisticated management system. GAP-NET will conduct trials for academic and biopharma industry partners using standardized instrument versions and administration. Collaboration with the Innovative Medicines Initiative (IMI) European Prevention of Alzheimer's Disease (EPAD) program, the Canadian Consortium on Neurodegeneration in Aging (CCNA) and other similar international initiatives will allow conduct of global trials. GAP-NET aims to increase trial efficiency and quality, decrease trial redundancy, accelerate cohort development and trial recruitment, and decrease trial costs. The value proposition for sites includes stable funding and uniform training and trial execution; the value to trial sponsors is decreased trial costs, reduced time to execute trials, and enhanced data quality. The value for patients and society is the more rapid availability of new treatments for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.